Abstract
In the era of personalized medicine, “targeted radionuclide therapy” (TRT) is designed to damage only the cancerous cells while sparing unnecessary damage to the adjacent healthy cells/tissues. Unlike conventional external beam radiation therapy, TRT is intended to cause less or no collateral damage to normal tissues, as it aims at achieving targeted drug delivery either to a clinically diagnosed cancer not amenable to surgery or to metastatic tumor cells and tumor cell clusters, thus providing systemic therapy of cancer. Currently there are hundreds of new pathway-targeted anticancer agents undergoing phase II and phase III clinical trials. TRT is just one type within the domain of “targeted therapies.” In addition to the effective targeted radiopharmaceuticals already well validated for routine clinical use, newer radiolabeled agents are still in the phase of either preclinical or clinical validation.
This chapter describes the main physical and radiochemical characteristics of radionuclides that have potential or have already been employed to label biologically reactive molecules for the development of novel radiopharmaceuticals for therapy. Some of these agents have entered advanced clinical trials in tumor-bearing patients. Results of these clinical trials cover a wide spectrum of potential clinical usefulness.
The chapter is divided into two main parts depending on the type of particle emission (α or β− associated or not with the emission of either γ-rays or β+ particles). Within each domain, there is some exchange of experience and shift of focus in the various phases of development, depending on the modalities of ascertaining efficient tumor targeting according to the principles of theranostics. Theranostics is often performed utilizing the same molecule labeled with two different radionuclides, one radionuclide for imaging and another for therapy, in order to achieve a personalized treatment approach to the patient. Nowadays, the fields of interest include the well-established use of radioactive iodine in differentiated thyroid cancer, radiolabeled metaiodobenzylguanidine (MIBG) in neuroblastoma, and the clinical impact of peptide receptor radionuclide therapy (PRRT) in the management of neuroendocrine tumors. Furthermore, the more cutting-edge and recently introduced theranostic approaches will be reviewed, such as the radioligand therapy with 177Lu-PSMA-ligand and targeted alpha therapy in castration-resistant prostate cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- ALP:
-
Alkaline phosphatase
- AUNP:
-
Gold nanoparticle
- BBN:
-
Bombesin
- BsMAb:
-
Bispecific monoclonal antibody
- CAIX:
-
Carbonic anhydrase isoenzyme 9
- ccRCC:
-
Clear-cell renal carcinoma
- CEA:
-
Carcinoembryonic antigen
- CI:
-
Confidence interval
- DOTA:
-
2-(4-isothiocyanatobenzyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (macrocyclic coupling agent to label compounds of biological interest with metal radionuclides)
- EBRT:
-
External beam radiation therapy
- ECM:
-
Extracellular matrix
- EDTMP:
-
Ethylenediamine tetra(methylene phosphonic acid)
- EMA:
-
European Medicines Agency
- FDA:
-
Food and Drug Administration of the United States of America
- FN:
-
Fibronectin
- GA:
-
Arabic glycoprotein
- HA:
-
Hydroxyapatite
- HAMA:
-
Human anti-mouse antibody
- HER2:
-
Human epidermal growth factor receptor 2, also known as receptor tyrosine-protein kinase erbB-2, or HER2/neu
- HSG:
-
Histamine-succinyl-glutamine hapten
- L-19 SIP:
-
Small immunoreactive protein, (scFv) 2, derived from monoclonal antibody L19
- L-19:
-
Monoclonal antibody recognizing the EDB domain of fibronectin
- MAA:
-
Macroaggregated albumin
- mAb:
-
Monoclonal antibody
- mCRPC:
-
Metastatic castrate-resistant prostate cancer
- MIBG:
-
Metaiodobenzylguanidine
- MTA-1:
-
Metastasis-associated protein encoded by the MTA1 gene
- MTC:
-
Medullary thyroid cancer
- MTD:
-
Maximum tolerated dose
- MTRD:
-
Maximum tolerated radiation dose
- MX35:
-
A monoclonal antibody recognizing the sodium-dependent phosphate transport protein 2b
- NaPi2b:
-
Sodium-dependent phosphate transport protein 2b
- NCA:
-
No-carrier-added
- NHL:
-
Non-Hodgkin’s lymphoma
- PAI2-uPAR:
-
Proteases, members of the urokinase-type plasminogen activator family
- PCa:
-
Prostatic carcinoma
- PET:
-
Positron emission tomography
- PRRT:
-
Peptide receptor radionuclide therapy
- PSA:
-
Prostate-specific antigen
- PSMA:
-
Prostate-specific membrane antigen
- RE:
-
Radioembolization
- RIT:
-
Radioimmunotherapy
- [211At]SAPC:
-
N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate
- SCID:
-
Severe combined immunodeficiency
- SPECT:
-
Single-photon emission computed tomography
- SRE:
-
Skeletal-related event
- TAT:
-
Targeted alpha therapy
- TCMC:
-
2-(4-isothiocyanatobenzyl-1,4,7,10-tetraaza-1,4,7,10-tetra-(2-carbamonylmetyl)-cyclododecane (macrocyclic coupling agent to label compounds of biological interest with metal radionuclides)
- Theranostic:
-
An agent with both diagnostic and therapeutic capabilities (e.g., 131I-iodide, in low activity it is a diagnostic agent; in high activity it is a therapeutic agent)
- TROP-2:
-
Cell-surface glycoprotein overexpressed in adenocarcinomas, correlated with tumor aggressiveness
- TRT:
-
Targeted radionuclide therapy
- VGEF:
-
Vascular endothelial growth factor
- WHO:
-
World Health Organization
References
Sgouros G, Roeske JC, McDevitt MR, et al. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51:311–28.
Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12:6250s–7.
Henriksen G, Breistol K, Bruland OS, et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 2002;62:3120–5.
Henriksen G, Fisher DR, Roeske JC, et al. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med. 2003;44:252–9.
Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des. 2000;6:1433–55.
Miederer M, McDevitt MR, Sgouros G, et al. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med. 2004;45:129–37.
Zalutsky MR, Garg PK, Friedman HS, Bigner DD. Labeling monoclonal antibodies and F(ab′)2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci USA. 1989;86:7149–53.
Reist CJ, Foulon CF, Alston K, Bigner DD, Zalutsky MR. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. Nucl Med Biol. 1999;26:405–11.
Orozco JJ, Bäck T, Kenoyer A, et al. Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. Blood. 2013;121:3759–67.
Zalutsky MR, Reardon DA, Akabani G, et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008;49:30–8.
Andersson H, Cederkrantz E, Bäck T, et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of 211At-MX35 F(ab′)2 – a phase I study. J Nucl Med. 2009;50:1153–60.
Boll RA, Malkemus D, Mirzadeh S. Production of actinium-225 for alpha particle mediated radioimmunotherapy. Appl Radiat Isot. 2005;62:667–79.
Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem. 2005;77:6288–91.
Apostolidis C, Molinet R, McGinley J, et al. Cyclotron production of Ac-225 for targeted alpha therapy. Appl Radiat Isot. 2005;62:383–7.
Miederer M, Scheinberg DA, McDevitt MR. Realizing the potential of the actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev. 2008;60:1371–82.
Borchardt PE, Yuan RR, Miederer M, et al. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res. 2003;63:5084–90.
Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C, et al. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res. 2009;69:8941–8.
Woodward J, Kennel SJ, Stuckey A, et al. LaPO4 nanoparticles doped with actinium-225 that partially sequesters daughter radionuclides. Bioconjug Chem. 2011;22:766–76.
McLaughlin MF, Robertson D, Pevsner PH, et al. LnPO 4 nanoparticles doped with Ac-225 and sequestered daughters for targeted alpha therapy. Cancer Biother Radiopharm. 2014;29:34–41.
McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537–40.
Jurcic JG, Rosenblat TL, McDevitt MR, et al. Phase I trial of the targeted alpha-particle nano-generator actinium-225 (225Ac-lintuzumab) (anti- CD33; HuM195) in acute myeloid leukemia (AML). J Clin Oncol. 2011;29:651–6.
Dawicki W, Allen KJH, Jiao R, et al. Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors. Oncoimmunology. 2019;8(8):1607673.
Meredith R, Torgue J, Shen S, et al. Dose escalation and dosimetry of first-in-human radioimmunotherapy with 212Pb-TCMC-trastuzumab. J Nucl Med. 2014;55:1636–42.
Meredith RF, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, et al. Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm. 2014;29:12–7.
Schwartz J, Jaggi JS, O’Donoghue JA, et al. Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phys Med Biol. 2011;56:721–33.
Benešová M, Schäfer M, Bauder-Wüst U, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–20.
Benešová M, Bauder-Wüst U, Schäfer M, et al. Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors. J Med Chem. 2016;59:1761–75.
Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. J Nucl Med. 2016;57:1170–6.
Ahmadzadehfar H, Rahbar K, Kürpig S, et al. Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5(1):114.
Ahmadzadehfar H, Eppard E, Kürpig S, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7:12477–88.
Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941–4.
Heyerdahl H, Abbas N, Sponheim K, et al. Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice. Curr Radiopharm. 2013;6:106–16.
Hagemann UB, Ellingsen C, Schuhmacher J, et al. Mesothelin-targeted thorium-227 conjugate (MSLN-TTC): preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers. Clin Cancer Res. 2019;25:4723–34.
O’Donoghue JA, Bardiès M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36:1902–9.
Boudousq V, Bobyk L, Busson M, et al. Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS One. 2013;8:e69613.
De Vincentis G, Gerritsen W, Gschwend JE, et al. Advances in targeted alpha therapy for prostate cancer. Ann Oncol. 2019;30:1728–39.
McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998;25:1341–51.
Jurcic JG, Pandit-Taskar N, Divgi CR, et al. Alpha particle immunotherapy for acute myeloid leukemia (AML) with bismuth-213 and actinium-225 [abstract]. Cancer Biother Radiopharm. 2006;21:396.
McLaughlin MF, Woodward J, Boll RA, et al. Gold coated lanthanide phosphate nanoparticles for targeted alpha generator radiotherapy. PLoS One. 2013;8:e54531.
Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233–9.
Królicki L, Kunikowska J, Bruchertseifer F, et al. 225Ac- and 213Bi-substance P Analogues for Glioma Therapy. Semin Nucl Med. 2020;50:141–151.
Chérel M, Gouard S, Gaschet J, et al. 213Bi Radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. J Nucl Med. 2013;54:1597–604.
http://www.arevamed.areva.com/EN/home-134/nuclear-medicine.html#tab=tab3
Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. 212Pb-radioimmunotherapy induces G2 cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Mol Cancer Ther. 2012;11:639–48.
Yong KJ, Milenic DE, Baidoo KE, et al. Gene expression profiling upon 212Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model. Cancer Med. 2013;2:646–53.
Ruegg CL, Anderson-Berg ET, Brechbiel MW, et al. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res. 1990;50:4221–6.
Chappell LL, Dadachova E, Milenic DE, et al. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotope 203Pb and 212Pb. Nucl Med Biol. 2000;27:93–100.
Ruble G, Wu C, Squire RA, et al. The use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia. Int J Radiat Oncol Biol Phys. 1996;34:609–16.
McMurry TJ, Brechbiel MW, Kumar K, Gansow OA. Convenient synthesis of bifunctional tetraaza macrocycles. Bioconjug Chem. 1992;3:108–17.
Milenic DE, Garmestani K, Brady ED, et al. Alpha-particle radioimmunotherapy of disseminated peritoneal diseases using a 212Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm. 2005;20:557–66.
Andersson H, Elgqvist J, Horvath G, et al. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clin Cancer Res. 2003;9:S3914–21.
Milenic DE, Baidoo KE, Kim YS, Brechbiel MW. Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease. MAbs. 2015;7:255–64.
Stallons TAR, Saidi A, Tworowska I, Delpassand ES, Torgue JJ. Preclinical investigation of 212Pb-DOTAMTATE for peptide receptor radionuclide therapy in a neuroendocrine tumor model. Mol Cancer Ther. 2019;18(5):1012–21.
Delpassand E, Tworowska I, Torgue J, et al. First-in-human dose escalation of AlphaMedix™ for targeted alpha-emitter therapy of NETs. J Nucl Med. 2020;61(Suppl 1):415.
Kostourou V, Papalazarou V. Non-collagenous ECM proteins in blood vessel morphogenesis and cancer. Biochim Biophys Acta. 2014;1840:2403–13.
Rosario T, DeSimone DW. The extracellular matrix in development and morphogenesis: a dynamic view. Dev Biol. 2010;341:126–40.
Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer. 2003;3:422–33.
Nicolò G, Salvi S, Oliveri G, et al. Expression of tenascin and of the ED-B containing oncofetal fibronectin isoform in human cancer. Cell Differ Dev. 1990;32:401–8.
Halin C, Zardi L, Neri D. Antibody-based targeting of angiogenesis. News Physiol Sci. 2001;16:191–4.
Castellani P, Viale G, Dorcaratto A, et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer. 1994;59:612–8.
Carnemolla B, Balza E, Siri A, et al. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol. 1989;108:1139–48.
Kaczmarek J, Castellani P, Nicolò G, et al. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer. 1994;59:11–6.
Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood. 2009;113:2265–74.
Locher R, Erba PA, Hirsch B, et al. Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of 131I-L19SIP in a prostate cancer patient. J Cancer Res Clin Oncol. 2014;140:35–43.
Pujuguet P, Hammann A, Moutet M, et al. Expression of fibronectin ED-A+ and ED-B+ isoforms by human and experimental colorectal cancer. Contribution of cancer cells and tumor- associated myofibroblasts. Am J Pathol. 1996;148:579–92.
D’Ovidio MC, Mastracchio A, Marzullo A, et al. Intratumoral microvessel density and expression of ED- A/ED-B sequences of fibronectin in breast carcinoma. Eur J Cancer. 1998;34:1081–5.
Karelina TV, Eisen AZ. Interstitial collagenase and the ED-B oncofetal domain of fibronectin are markers of angiogenesis in human skin tumors. Cancer Detect Prev. 1998;22:438–44.
Castellani P, Borsi L, Carnemolla B, et al. Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol. 2002;161:1695–700.
Pini A, Viti F, Santucci A, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem. 1998;273:21769–76.
Viti F, Tarli L, Giovannoni L, et al. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. 1999;59:347–52.
Demartis S, Tarli L, Borsi L, et al. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med. 2001;28:534–9.
Borsi L, Balza E, Bestagno M, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer. 2002;102:75–85.
Berndorff D, Borkowski S, Sieger S, et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res. 2005;11:7053s–63.
Tijink BM, Neri D, Leemans CR, et al. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med. 2006;47:1127–35.
Rybak JN, Trachsel E, Scheuermann J, Neri D. Ligand-based vascular targeting of disease. Chem Med Chem. 2007;2:22–40.
Santimaria M, Moscatelli G, Giovannoni L, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res. 2003;9:571–9.
Erba PA, Sollini M, Orciuolo E, Traino C, Petrini M, Paganelli G, et al. Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. J Nucl Med. 2012;53:922–7.
Poli G, Bianchi C, Virotta G, Bettini A, et al. Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol Res. 2013;1:134–43.
Qaim SM. Therapeutic radionuclides and nuclear data. Radiochim Acta. 2001;89:297–302.
Kondev FG. Nuclear data sheets for A = 177. Nucl Data Sheets. 2003;98:801–1095.
Hofman MS, Violet J, Hicks RJ, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018; 19:825–33.
Kratochwil C, Fendler WP, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46:2536–44.
Tagawa ST, Beltran H, Vallabhajosula S, et al. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer. 2010;116:1075–83.
O’Donnell RT, DeNardo SJ, Miers LA, et al. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate. 2002;50:27–37.
Sokoloff RL, Norton KC, Gasior CL, et al. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate. 2000;43:150–7.
Bostwick DG, Pacellim A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82:2256–61.
Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998;58:4055–60.
Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591–01.
Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182–91.
Barbet J, Peltier P, Bardet S, et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA X anti-DTPA-indium bispecific antibody. J Nucl Med. 1998;39:1172–8.
Goldenberg DM, Sharkey RM, Paganelli G, et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823–34.
Chatal J-F, Campion L, Kraeber-Bodéré F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:1705–11.
Schoffelen R, Boerman OC, Goldenberg DM, et al. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br J Cancer. 2013;109:934–42.
Schoffelen R, van der Weg W, Visser EP, et al. Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer. Eur J Nucl Med Mol Imaging. 2014;41:1593–02.
Schoffelen R, van der Graaf WTA, Franssen G, et al. Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med. 2010;51:1780–7.
Liu C, Brasic JR, Liu X, et al. Timing and optimized acquisition parameters for the whole-body imaging of 177Lu-EDTMP toward performing bone palliation treatment. Nucl Med Commun. 2012;33:90–6.
Dalm SU, Bakker IL, de Blois E, et al. 68Ga/177Lu-NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use in oncology. J Nucl Med. 2017; 58:293–9.
Karagiannis TC. Comparison of different classes of radionuclides for potential use in radioimmunotherapy. Hell J Nucl Med. 2007;10:82–8.
Unni PR, Solov SV, Chakraborty S, et al. 166Ho-HA: a new radiopharmaceutical for treatment of arthritis. BARC Newsl. 2006;208:1–8.
Unni PR, Chaudhury PR, Venkatesh M, et al. Preparation and evaluation of 166Ho labeled hydroxyapatite (HA) particles for radiosynovectomy. Nucl Med Biol. 2002;29:199–209.
Mumper RJ, Ryo UY, Jay M. Neutron-activated holmium-166-poly(L-lactic acid) microspheres: a potential agent for the internal radiation therapy of hepatic tumors. J Nucl Med. 1991;32:2139–43.
Mumper J, Mills BJ, Ryo UY, Jay M. Polymeric microspheres for radionuclide synovectomy containing neutron-activated holmium-166. J Nucl Med. 1992;33:398–402.
Smits ML, Nijsen JF, van den Bosch MA, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012;13:1025–34.
Prince JP, van den Bosch MAAJ, Nijsen JFW, et al. Efficacy of radioembolization with 166Ho-microspheres in salvage patients with liver metastases: a phase 2 study. J Nucl Med. 2018;59:582–8.
Mathew B, Chakraborty S, Das T, et al. 175Yb labeled polyaminophosphonates as potential agents for bone pain palliation. Appl Radiat Isot. 2004;60:635–42.
Sartor O. Overview of samarium Sm 153 lexidronam in the treatment of painful metastatic bone disease. Rev Urol. 2004;6:S3–S12.
Simón J, Frank RK, Crump DK, et al. A preclinical investigation of the saturation and dosimetry of 153Sm-DOTMP as a bone-seeking radiopharmaceutical. Nucl Med Biol. 2012;39:770–6.
Das T, Chakraborty S, Sarma HD, et al. 170Tm-EDTMP: a potential cost-effective alternative to 89SrCl2 for bone pain palliation. Nucl Med Biol. 2009;36:561–8.
DeNardo SJ, DeNardo GL, Kukis DL, et al. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med. 1999;40:302–10.
DeNardo GL, DeNardo SJ, O’Donnell RT, et al. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin’s lymphoma. Clin Lymphoma. 2000;1:118–26.
Delaloye AB, Delaloye B, Buchegger F, et al. Comparison of copper-67- and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors. J Nucl Med. 1997;38:847–53.
Chu SYF, Ekstrom LP, Firestone B. Table of isotopes decay data. The Lund/LBNL Nuclear Data Search. February 1999. Last accessed 19 Jul 2016.
Minarik D, Sjögreen Gleisner K, Ljungberg M. Evaluation of quantitative 90Y SPECT based on experimental phantom studies. Phys Med Biol. 2008;53:5689–03.
Dancey JE, Shepherd FA, Paul K, et al. Treatment of non resectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000;41:1673–81.
Kossert K, Schrader H. Activity standardization by liquid scintillation counting and half-life measurements of 90Y. Appl Radiat Isot. 2004;60:741–9.
Kyle V, Hazleman BL, Wraight PE. Yttrium-90 therapy and 99mTc pertechnetate knee uptake measurements in the management of rheumatoid arthritis. Ann Rheum Dis. 1983;42:132–7.
Smith T, Crawley JCW, Shawe DJ, Gumpel JM. SPECT using Bremsstrahlung to quantify 90Y uptake in Baker’s cysts: its application in radiation synovectomy of the knee. Eur J Nucl Med. 1988;14:498–503.
Otte A, Jermann E, Behe M, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med. 1997;24:792–5.
De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32:133–40.
Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457–70.
Leichner PK, Akabani G, Colcher D, et al. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. J Nucl Med. 1997;38:512–6.
Grady ED. Internal radiation therapy of hepatic cancer. Dis Colon Rectum. 1979;22:371–5.
Andrews JC, Walker SC, Ackermann RJ, et al. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med. 1994;35:1637–44.
Lau WY, Leung WT, Ho S, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer. 1994;70:994–9.
Kao YH, Steinberg JD, Tay YS, et al. Post-radioembolization yttrium-90 PET/CT – part 1: diagnostic reporting. JNMMI Res. 2013;3:56. https://doi.org/10.1186/2191-219X-3-56.
Hnatowich DJ, Virzi F, Doherty PW. DTPA-coupled antibodies labeled with Yttrium-90. J Nucl Med. 1985;26:503–9.
Wright CL, Werner JD, Tran JM, et al. Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review. J Vasc Interv Radiol. 2012;23:669–74.
Collins J, Salem R. Hepatic radioembolization complicated by gastrointestinal ulceration. Semin Interv Radiol. 2011;28:240–5.
Riaz A, Lewandowski RJ, Kulik LM, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol. 2009;20:1121–30.
Lhommel R, van Elmbt L, Goffette P, et al. Feasibility of90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres. Eur J Nucl Med Mol Imaging. 2010;37:1654–62.
Knight PJ, Dombos JF, Rosen D, et al. The use of interstitial radiation therapy in the treatment of persistent, localized, and unresectable cancer in children. Cancer. 1986;57:951–4.
Rich TA. Radiation therapy for pancreatic cancer: eleven year experience at the JCRT. Int J Radiat Oncol Biol Phys. 1985;11:759–63.
Dhar S, Gu FX, Langer R, et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008;105:17356–61.
Gommersall L, Shergill IS, Ahmed HU, et al. Nanotechnology in the management of prostate cancer. Br J Urol Int. 2008;102:1493–5.
Shulga OV, Zhou D, Demchenko AV, Stine KJ. Detection of free prostate specific antigen (fPSA) on a nanoporous gold platform. Analyst. 2008;133:319–22.
Thangapazham RL, Puri A, Tele S, et al. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol. 2008;32:1119–23.
Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007;28:869–76.
Grodzinski P, Silver M, Molnar LK. Nanotechnology for cancer diagnostics: promises and challenges. Expert Rev Mol Diagn. 2006;6:307–18.
Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng. 2007;9:257–88.
Portney NG, Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. Anal Bioanal Chem. 2006;384:620–30.
Sengupta S, Sasisekharan R. Exploiting nanotechnology to target cancer. Br J Cancer. 2007;96:1315–9.
Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther. 2006;5:1909–17.
Wang MD, Shin DM, Simons JW, Nie S. Nanotechnology for targeted cancer therapy. Expert Rev Anticancer Ther. 2007;7:833–7.
Bhattacharya R, Mukherjee P. Biological properties of “naked” metal nanoparticles. Adv Drug Deliv Rev. 2008;60:1289–306.
Mukherjee P, Bhattacharya R, Wang P, et al. Antiangiogenic properties of gold nanoparticles. Clin Cancer Res. 2005;11:3530–4.
Chanda N, Kan P, Watkinson LD, et al. Radioactive gold nanoparticles in cancer therapy: therapeutic efficacy studies of GA-198AuNP nanoconstruct in prostate tumor-bearing mice. Nanomedicine. 2010;6:201–9.
Hu F, Cutler CS, Hoffman T, et al. Pm-149 DOTA bombesin analogs for potential radiotherapy. In vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-betaAla-BBN(7-14)NH2. Nucl Med Biol. 2002;29:423–30.
Grazman B, Troutner DE. 105Rh as a potential radiotherapeutic agent. Appl Radiat Isot. 1988;39:257–60.
Goswami N, Higginbotham C, Volkert W, et al. Rhodium-105 tetrathioether complexes: radiochemistry and initial biological evaluation. Nucl Med Biol. 1999;26:951–7.
Ando A, Ando I, Tonami N, et al. Production of 105Rh–EDTMP and its bone accumulation. Appl Radiat Isot. 2000;52:211–5.
Pietrelli L, Mausner LF, Kolsky KL. Separation of carrier-free Sc-47 from titanium targets. J Radioanal Nucl Chem. 1992;157:335–45.
Müller C, Bunka M, Reber J, et al. Promises of cyclotron-produced 44Sc as a diagnostic match for trivalent β-emitters: in vitro and in vivo study of a 44Sc-DOTA-folate conjugate. J Nucl Med. 2013;54:2168–74.
Müller C, Zhernosekov K, Köster U, et al. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β-radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative. J Nucl Med. 2012;53:1951–9.
Pastorek J, Pastorekova S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene. 1994;9:2877–88.
Opavsky R, Pastorekova S, Zelnik V, et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics. 1996;33:480–7.
Grabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer. 2000;85:865–70.
Uemura H, Nakagawa Y, Yoshida K, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer. 1999;81:741–6.
Divgi CR, Bander NH, Scott AM, et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res. 1998;4:2729–39.
Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer. 1986;38:489–94.
Pastorekova S, Parkkila S, Parkkila AK, et al. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology. 1997;112:398–408.
Steffens MG, Boerman OC, de Mulder PH, Oyen WJ, Buijs WC, Witjes JA, et al. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res. 1999;5(10 Suppl):3268s–74.
Divgi CR, O’Donoghue JA, Welt S, et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med. 2004;45:1412–21.
Brouwers AH, Mulders PF, de Mulder PH, et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol. 2005;23:6540–8.
Brouwers AH, Buijs WC, Mulders PF, et al. Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. Clin Cancer Res. 2005;11(19 Pt 2):7178s–6.
Stillebroer AB, Boerman OC, Desar IM, et al. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 2013;64:478–85.
Stillebroer AB, Zegers CM, Boerman OC, et al. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging. J Nucl Med. 2012;53:82–9.
Divgi CR, Uzzo RG, Gatsonis C, et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol. 2013;31:187–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Guidoccio, F., Mazzarri, S., Depalo, T., Orsini, F., Erba, P.A., Mariani, G. (2022). Novel Radiopharmaceuticals for Therapy. In: Volterrani, D., Erba, P.A., Strauss, H.W., Mariani, G., Larson, S.M. (eds) Nuclear Oncology. Springer, Cham. https://doi.org/10.1007/978-3-031-05494-5_36
Download citation
DOI: https://doi.org/10.1007/978-3-031-05494-5_36
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-05493-8
Online ISBN: 978-3-031-05494-5
eBook Packages: MedicineReference Module Medicine